Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-03-01-2001
Volume0
Issue 0

Privacy, Pediatrics, and Policy

Author(s):

Jill Wechsler, Pharm Exec’s Washington Correspondent

FDA proposals for expanding the pediatric study program include tax incentives and }transferable exclusivity.}

Articles in this issue
Research: New Horizons
Earnings: Tough Times Ahead
Outbreak: Anthrax Alarm
Patents: China on the Genome Map
Privacy, Pediatrics, and Policy
Lilly's International Family

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 23rd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 23rd 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 23rd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 23rd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 23rd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 23rd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor